GAMMADELTA THERAPEUTICS LTD
Get an alert when GAMMADELTA THERAPEUTICS LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-12-31 (in 7mo)
Last filed for 2025-03-31
Confirmation statement due
2026-06-30 (in 1mo)
Last made up 2025-06-16
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£131M
-4.9% vs 2024
Employees
—
Average over period
Profit before tax
-£8M
-31.5% vs 2024
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2025-03-31
| Metric | Trend | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Turnover | £22,960,002 | £2,809,574 | |
| Operating profit | -£5,491,854 | -£7,851,607 | |
| Profit before tax | -£5,953,807 | -£7,829,492 | |
| Net profit | -£4,352,108 | -£6,748,092 | |
| Cash | — | — | |
| Total assets less current liabilities | £163,586,567 | £155,707,108 | |
| Net assets | £137,643,298 | £130,895,206 | |
| Equity | £137,643,298 | £130,895,206 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Operating margin | -23.9% | -279.5% | |
| Net margin | -19.0% | -240.2% | |
| Return on capital employed | -3.4% | -5.0% | |
| Current ratio | -10.17x | -16.41x | |
| Interest cover | -11.89x | -65430.06x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have prepared the financial statements on the going concern basis as they do not intend to liquidate the Company or to cease its operations, and as they have concluded that the Company's financial position means that this is realistic. They have also concluded that there are no material uncertainties that could have cast significant doubt over its ability to continue as a going concern for at least a year from the date of approval of the financial statements ("the going concern period").”
Group structure
- GAMMADELTA THERAPEUTICS LTD · parent
- Lymphocyte Activation Technologies, S.A. 100%
- Adaptate Biotherapeutics Ltd 100%
Significant events
- “Following the acquisition of the Company by Takeda Pharmaceutical Company Limited on 5 April 2022, the, Company expects to accelerate development of allogeneic γδ T cell immunotherapies.”
- “On 15 September 2023, the Company received dividend income totalling £131,190,071 from the subsidiary undertaking Adaptate Biotherapeutics Ltd. Subsequently, the directors reviewed the recoverable value of the subsidiary and recorded an impairment loss of £129,077,078 accordingly.”
- “Subsequent to the year end, on 3 April 2025 the subsidiary undertaking Lymphocyte Activation Technologies, S.A. was liquidated, and furthermore on 8 July 2025 the subsidiary undertaking Adaptate Biotherapeutics Ltd was dissolved.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 12 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| DRISCOLL, Bryan | Secretary | 2022-04-05 | — | — |
| MEMIS, Seyda Atadan | Director | 2022-08-01 | Mar 1979 | Turkish |
| ROFFE, Emma Jane, Dr | Director | 2022-04-05 | Mar 1972 | British |
Show 12 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GIBBONS, Mark | Director | 2022-04-05 | 2022-11-08 |
| GOODFELLOW, Peter Neville | Director | 2016-08-15 | 2022-04-05 |
| HAINES, Timothy John | Director | 2016-09-09 | 2022-04-05 |
| HAYDAY, Adrian Clive, Professor | Director | 2016-08-15 | 2022-04-05 |
| HUET, Heather Adkins, Dr | Director | 2021-04-01 | 2022-07-22 |
| KEMP, Daniel Matthew | Director | 2017-05-08 | 2021-04-01 |
| MEHTA, Raj | Director | 2016-06-17 | 2017-02-09 |
| NEAL, Jonathan Clark | Director | 2022-04-05 | 2023-01-18 |
| OWEN, Michael John | Director | 2016-08-15 | 2022-04-05 |
| PAOLETTI, Paolo, Dr | Director | 2017-02-09 | 2022-04-05 |
| PARKER, Stephen Barry, Dr | Director | 2016-09-09 | 2017-06-09 |
| SHIELDS, John Gerard, Dr | Director | 2016-08-15 | 2016-09-09 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Abingworth Bioventures Vi Gp Lp | Corporate entity | Shares 25–50%, Voting 25–50%, Appoints directors | 2017-07-24 | Ceased 2022-04-05 |
| Takeda Pharmaceutical Company Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2017-05-08 | Active |
| Abingworth Llp | Corporate entity | Shares 25–50%, ownership-of-shares-25-to-50-percent-as-trust, Appoints directors | 2016-08-15 | Ceased 2017-07-24 |
Filing timeline
Last 20 of 127 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-18 | AA | accounts | Accounts with accounts type full | |
| 2025-07-18 | AA | accounts | Accounts with accounts type full | |
| 2025-06-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-06-11 | DISS40 | gazette | Gazette filings brought up to date | |
| 2025-06-03 | GAZ1 | gazette | Gazette notice compulsory | |
| 2025-01-17 | AAMD | accounts | Accounts amended with accounts type full | |
| 2024-11-29 | AD02 | address | Change sail address company with old address new address | |
| 2024-07-07 | AA | accounts | Accounts with accounts type full | |
| 2024-06-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-06-01 | DISS40 | gazette | Gazette filings brought up to date | |
| 2024-05-28 | GAZ1 | gazette | Gazette notice compulsory | |
| 2024-02-19 | CH01 | officers | Change person director company with change date | |
| 2024-01-11 | AD02 | address | Change sail address company with old address new address | |
| 2023-06-22 | AD03 | address | Move registers to sail company with new address | |
| 2023-06-21 | AD02 | address | Change sail address company with new address | |
| 2023-06-21 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-01-26 | TM01 | officers | Termination director company with name termination date | |
| 2023-01-03 | AA | accounts | Accounts with accounts type group | |
| 2022-11-10 | TM01 | officers | Termination director company with name termination date | |
| 2022-09-29 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2024 → FY2025 · period ending 2025-03-31 vs 2024-03-31
-
Turnover
-87.8%
£22,960,002 £2,809,574
-
Cash
—
Not reported
-
Net assets
-4.9%
£137,643,298 £130,895,206
-
Employees
—
Not reported
-
Operating profit
-43%
-£5,491,854 -£7,851,607
-
Profit before tax
-31.5%
-£5,953,807 -£7,829,492
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers